ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

ClinicalTrials.gov ID: NCT02115048

Public ClinicalTrials.gov record NCT02115048. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Open-label Phase II Study of Letrozole Plus Afatinib Versus Letrozole Alone in First-line Treatment of Advanced ER+, HER2- Postmenopausal Breast Cancer With Low ER Expression

Study identification

NCT ID
NCT02115048
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Translational Research in Oncology
Other
Enrollment
44 participants

Conditions and interventions

Interventions

  • Afatinib Drug
  • Letrozole Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2014
Primary completion
Oct 31, 2018
Completion
Oct 31, 2018
Last update posted
Dec 25, 2019

2014 – 2018

United States locations

U.S. sites
9
U.S. states
4
U.S. cities
9
Facility City State ZIP Site status
St. Jude Heritage Healthcare Fullerton California 92835
University of California Los Angeles Hematology Oncology Los Angeles California 90095
West Valley Hematology Oncology Medical Group Northridge California 91328
DBA Torrance Memorial Physician Network/Cancer Care Associates Redondo Beach California 90277
Coastal Integrative Cancer Care San Luis Obispo California 93401
Central Coast Medical Oncology Corporation Santa Maria California 93454
Orlando Health, Inc. Orlando Florida 32806
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
Hope Women's Cancer Centers Asheville North Carolina 28806

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02115048, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 25, 2019 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02115048 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →